Business Context and Reporting Period
This Form 8-K filing by Helix Acquisition Corp. II (not Bridgebio Oncology Therapeutics, Inc.) reports the consummation of its Initial Public Offering (IPO) and a concurrent Private Placement on February 13, 2024. The company is a Cayman Islands-based Special Purpose Acquisition Company (SPAC) and an emerging growth company.
Key Financial Metrics
- IPO Gross Proceeds: $184,000,000 from the sale of 18,400,000 Class A ordinary shares at $10.00 per share (including full exercise of the 2,400,000 share over-allotment).
- Private Placement Proceeds: $5,090,000 from the sale of 509,000 Class A ordinary shares to Helix Holdings LLC at $10.00 per share.
- Total Funds in Trust: $184,000,000 placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company.
- Deferred Underwriting Fees: $5,520,000 included within the trust account balance.
- Profit, Cash Flow, Margins, Debt: The filing text does not provide specific values for operating profit, cash flow, margins, or debt obligations outside of the transaction proceeds and deferred fees.
Material Changes
This filing represents the initial capitalization event for the registrant. There is no prior comparable period for financial performance as the company was formed for the purpose of this IPO. The primary material change is the transition from a pre-IPO entity to a publicly traded company with $184 million in trust assets.
Guidance, Outlook, and Risks
The filing confirms the successful closing of the IPO and the placement of proceeds into a trust account, a standard requirement for SPACs to preserve capital for a future business combination. The text does not provide specific management commentary on future targets, detailed risk factors, or contingencies beyond the standard disclosure of the transaction mechanics. An audited balance sheet as of February 13, 2024, is referenced as Exhibit 99.1.
Investor Verification Checklist
- Verify the full terms of the underwriting agreement and the $5,520,000 deferred fee structure.
- Review the audited balance sheet (Exhibit 99.1) to confirm the exact cash position and any initial working capital outside the trust.
- Confirm the identity and background of the sponsor, Helix Holdings LLC, and the terms of the Private Placement Shares.
- Monitor subsequent filings for the identification of a target business combination and the timeline for redemption rights.